Literature DB >> 17785353

The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms.

Claudio Pagano1, Catia Pilon, Alessandra Calcagno, Riccardo Urbanet, Marco Rossato, Gabriella Milan, Katiuscia Bianchi, Rosario Rizzuto, Paolo Bernante, Giovanni Federspil, Roberto Vettor.   

Abstract

BACKGROUND: The endogenous cannabinoid system participates in the regulation of energy balance, and its dysregulation may be implicated in the pathogenesis of obesity. Adipose tissue endocannabinoids may produce metabolic and endocrine effects, but very few data are available in human adipose tissue and in primary human fat cells. EXPERIMENTAL
DESIGN: We measured expression of type 1 and type 2 cannabinoid receptors (CNR), enzymes of cannabinoids synthesis and degradation in human omental, sc abdominal, and gluteal adipose tissue from lean and obese subjects. Furthermore, we assessed the effect of CNR1 stimulation on glucose uptake and intracellular transduction mechanisms in primary human adipocytes. Then we assessed the reciprocal regulation between CNR1 and peroxisome proliferator-activated receptor-gamma (PPARgamma). Finally, we tested whether leptin and adiponectin are regulated by CNR1 in human adipocytes.
RESULTS: We found that most genes of the endocannabinoid system are down-regulated in gluteal fat and up-regulated in visceral and sc abdominal adipose tissue of obese patients. Treatment of adipocytes with rosiglitazone markedly down-regulated CNR1 expression, whereas Win 55,212 up-regulated PPARgamma. Win 55,212 increased (+50%) glucose uptake, the translocation of glucose transporter 4, and intracellular calcium in fat cells. All these effects were inhibited by SR141716 and wortmannin and by removing extracellular calcium. Win 55,212 and SR141716 had no effect on expression of adiponectin and leptin.
CONCLUSIONS: These results indicate a role for the local endocannabinoids in the regulation of glucose metabolism in human adipocytes and suggest a role in channeling excess energy fuels to adipose tissue in obese humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785353     DOI: 10.1210/jc.2007-0768

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  58 in total

1.  Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats.

Authors:  Mónica Alonso; Antonia Serrano; Margarita Vida; Ana Crespillo; Laura Hernandez-Folgado; Nadine Jagerovic; Pilar Goya; Carmen Reyes-Cabello; Vidal Perez-Valero; Juan Decara; Manuel Macías-González; Francisco Javier Bermúdez-Silva; Juan Suárez; Fernando Rodríguez de Fonseca; Francisco Javier Pavón
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Dual role of PPAR-γ in induction and expression of behavioral sensitization to cannabinoid receptor agonist WIN55,212-2.

Authors:  Leili Enayatfard; Farzaneh Rostami; Sanaz Nasoohi; Shahrbanoo Oryan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Neuromolecular Med       Date:  2013-06-21       Impact factor: 3.843

Review 4.  Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle.

Authors:  Cristoforo Silvestri; Alessia Ligresti; Vincenzo Di Marzo
Journal:  Rev Endocr Metab Disord       Date:  2011-09       Impact factor: 6.514

5.  Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.

Authors:  M Bajzer; M Olivieri; M K Haas; P T Pfluger; I J Magrisso; M T Foster; M H Tschöp; K A Krawczewski-Carhuatanta; D Cota; S Obici
Journal:  Diabetologia       Date:  2011-10-11       Impact factor: 10.122

Review 6.  The dysregulation of the endocannabinoid system in diabesity-a tricky problem.

Authors:  Thomas Scherer; Christoph Buettner
Journal:  J Mol Med (Berl)       Date:  2009-03-17       Impact factor: 4.599

Review 7.  The endocannabinoid system in obesity and type 2 diabetes.

Authors:  V Di Marzo
Journal:  Diabetologia       Date:  2008-06-18       Impact factor: 10.122

8.  CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.

Authors:  Tony Jourdan; Louiza Djaouti; Laurent Demizieux; Joseph Gresti; Bruno Vergès; Pascal Degrace
Journal:  Diabetes       Date:  2010-01-28       Impact factor: 9.461

9.  The endocannabinoid system links gut microbiota to adipogenesis.

Authors:  Giulio G Muccioli; Damien Naslain; Fredrik Bäckhed; Christopher S Reigstad; Didier M Lambert; Nathalie M Delzenne; Patrice D Cani
Journal:  Mol Syst Biol       Date:  2010-07       Impact factor: 11.429

Review 10.  Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.

Authors:  Helen Butler; Márta Korbonits
Journal:  Eur J Endocrinol       Date:  2009-09-03       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.